Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Pliant Therapeutics, Inc. - Common Stock
(NQ:
PLRX
)
1.350
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pliant Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis
December 15, 2022
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
December 02, 2022
Via
Benzinga
Pliant Therapeutics to Participate in Upcoming Investor Conferences
November 15, 2022
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Where Pliant Therapeutics Stands With Analysts
↗
September 01, 2022
Analysts have provided the following ratings for Pliant Therapeutics (NASDAQ:PLRX) within the last quarter:
Via
Benzinga
Expert Ratings for Pliant Therapeutics
↗
August 09, 2022
Within the last quarter, Pliant Therapeutics (NASDAQ:PLRX) has observed the following analyst ratings:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
↗
December 14, 2022
Via
Benzinga
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 08, 2022
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
3 Soaring Biotech Stocks That Could Climb Much Higher
↗
October 20, 2022
These drugmakers have bucked the overall market's downward trend this year and expectations are still high.
Via
The Motley Fool
Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary/Lung Disease Mini-Symposium
October 05, 2022
From
Pliant Therapeutics, Inc.
Via
GlobeNewswire
Why Adamis Pharmaceuticals Is Trading Lower By Around 44%, Here Are 46 Stocks Moving In Wednesday's Mid-Day Session
↗
September 21, 2022
Gainers
Via
Benzinga
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday
↗
September 22, 2022
Gainers
Via
Benzinga
Pliant Therapeutics Inc. (NASDAQ: PLRX) Climbs to New 52-Week High
September 14, 2022
Via
Investor Brand Network
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
↗
September 01, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022
↗
September 01, 2022
Upgrades
Via
Benzinga
7 Cheap Biotech Stocks to Buy Now
↗
August 03, 2022
These cheap biotech stocks to buy offer investors a way to get ready for the inevitable comeback in the biopharmaceutical sector.
Via
InvestorPlace
Pliant Therapeutics Secures FDA Fast Track Status For Liver Disease Drug
↗
July 21, 2022
Pliant Therapeutics (NASDAQ: PLRX) received Fast Track designation for its lead asset PLN-74809 from the U.S. Food and Drug Administration (FDA) for the potential treatment of primary sclerosing...
Via
Benzinga
4 Analysts Have This to Say About Pliant Therapeutics
↗
July 20, 2022
Over the past 3 months, 4 analysts have published their opinion on Pliant Therapeutics (NASDAQ:PLRX) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022
↗
July 20, 2022
Upgrades
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca's COVID-19 Vaccine As Effective As mRNA Shots, Humanigen's Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth's Alzheimer's Program
↗
July 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Boeing, PriceSmart And 80 Biggest Movers From Yesterday
↗
July 13, 2022
Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share.
Via
Benzinga
Why Is Canoo Surging By 80%? 52 Stocks Moving In Tuesday's Mid-Day Session
↗
July 12, 2022
Gainers
Via
Benzinga
Short Volatility Alert: Pliant Therapeutics, Inc.
↗
July 12, 2022
On Monday, shares of Pliant Therapeutics, Inc. (NASDAQ: PLRX) experienced volatile short activity. After the activity, the stock price went up +159.01% to $23.00. The overall sentiment for PLRX has...
Via
Benzinga
The Daily Biotech Pulse: GSK To Supply 50M Flu Vaccine Doses To US, FDA Lifts Hold On Greenwich's Cancer Immunotherapy Trial, Connect Biopharma Sees CBP-201 Topline Data Sooner
↗
July 12, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
What's Going On With Pliant Therapeutics Stock?
↗
July 12, 2022
Pliant Therapeutics Inc (NASDAQ: PLRX) shares are trading lower Tuesday after the company announced a proposed $150 million offering.
Via
Benzinga
Alibaba, Zoom Video And 76 Biggest Movers From Yesterday
↗
July 12, 2022
Gainers Kaspien Holdings Inc. (NASDAQ: KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the stock on social media.
Via
Benzinga
After-Hours Alert: Why Pliant Therapeutics Stock Is Moving
↗
July 11, 2022
Pliant Therapeutics Inc (NASDAQ: PLRX) shares are volatile in Monday's after-hours session after the company announced a proposed $150 million offering.
Via
Benzinga
Dow Dips Around 90 Points; La Jolla Pharmaceutical Shares Surge
↗
July 11, 2022
U.S. stocks traded lower toward the end of trading as investors digested the recent jobs report for the month of June.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
July 11, 2022
Via
Benzinga
Stocks Lower Midday as Tech Slumps
↗
July 11, 2022
Stocks are lower midday, with the Dow Jones Industrial Average and Nasdaq Composite both down triple digits, as investors prepare for this week's inflation data and the start of earnings season.
Via
Talk Markets
Pliant Therapeutics Stock Just Doubled And Hit A 10-Month High — Here's Why
↗
July 11, 2022
The company's IPF treatment is proving itself where others didn't.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
